Huai-An Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huai-An Chen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jyh-Ping Chen
Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan
7 shared publications Yu-Jen Lu
Department of Neurosurgery, Chang Gung Memorial Hospital, Linkou, Kwei-San, Taoyuan 33305, Taiwan; College of Medicine, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan
4 shared publications- Anilkumar Thaghalli Shivanna
Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan
3 shared publications - Ching-Li Tseng
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan
2 shared publications Gils Jose
2 shared publicationsHao-Lung Hsu
2 shared publications
Latest Publications
- Open Access
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10  (29) , 31693-31705
PEDOT:PSS-Loaded Gelatin Cryogels for Electrically Controlled Drug Release
Conductive cryogel is a new form of biomaterial that provides additional electrical properties, expanding its applications in biomedical engineering, particularly in tissue regeneration, such as neural and muscle tissues, and in drug-delivery systems. In this study, the gelatin cryogels (GCs) incorporating the conductive polymer PEDOT:PSS (PGC) at an optimal ratio (PGC2) could achieve suitable conductivity as an electrically responsive scaffold applied for controlled drug release. The characterization results demonstrated that PGC2 exhibited a well-defined porous structure (90-190 Οm), a favorable water uptake capacity (2738.4%), degradability (26.1% degradation after 24 h), and reversible deformability upon compression, demonstrating its suitability for minimally invasive procedures via injection. The electron-transfer capability and higher conductivity of PGC2 were also confirmed by examining the electrochemical properties, which revealed a lower impedance (0.0174 MΊ) compared to nonconductive GC2 (0.0208 MΊ). Additionally, drug release tests revealed that drugs contained in PGC2 as electrically responsive scaffolds had a higher release response to electrical stimulation (ES) (23%) compared to the one without ES (7%). Cytocompatibility assays revealed that NIH-3T3 cells cocultured on PGC2 and those cultured with a PGC2 extraction solution exhibited cell viability above 70%, indicating nontoxicity, as confirmed by a WST-1 assay and a live/dead staining assay. Overall, PGC2 represents a promising biomaterial with injectability, conductivity, and cytocompatibility, offering potential applications in regenerative medicine, drug delivery, and bioelectronic scaffolding.
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10  (29) , 31693-31705
Open AccessPEDOT:PSS-Loaded Gelatin Cryogels for Electrically Controlled Drug Release
Conductive cryogel is a new form of biomaterial that provides additional electrical properties, expanding its applications in biomedical engineering, particularly in tissue regeneration, such as neural and muscle tissues, and in drug-delivery systems. In this study, the gelatin cryogels (GCs) incorporating the conductive polymer PEDOT:PSS (PGC) at an optimal ratio (PGC2) could achieve suitable conductivity as an electrically responsive scaffold applied for controlled drug release. The characterization results demonstrated that PGC2 exhibited a well-defined porous structure (90-190 Οm), a favorable water uptake capacity (2738.4%), degradability (26.1% degradation after 24 h), and reversible deformability upon compression, demonstrating its suitability for minimally invasive procedures via injection. The electron-transfer capability and higher conductivity of PGC2 were also confirmed by examining the electrochemical properties, which revealed a lower impedance (0.0174 MΊ) compared to nonconductive GC2 (0.0208 MΊ). Additionally, drug release tests revealed that drugs contained in PGC2 as electrically responsive scaffolds had a higher release response to electrical stimulation (ES) (23%) compared to the one without ES (7%). Cytocompatibility assays revealed that NIH-3T3 cells cocultured on PGC2 and those cultured with a PGC2 extraction solution exhibited cell viability above 70%, indicating nontoxicity, as confirmed by a WST-1 assay and a live/dead staining assay. Overall, PGC2 represents a promising biomaterial with injectability, conductivity, and cytocompatibility, offering potential applications in regenerative medicine, drug delivery, and bioelectronic scaffolding.
- Top Cited PapersOpen Access
- 24 February 2025
- Published by Elsevier in Biomaterials
- Vol. 319, 123205
Platelet-derived extracellular vesicle drug delivery system loaded with kaempferol for treating corneal neovascularization
- 24 February 2025
- Published by Elsevier in Biomaterials
- Vol. 319, 123205
Top Cited PapersOpen AccessPlatelet-derived extracellular vesicle drug delivery system loaded with kaempferol for treating corneal neovascularization
- Open Access
- 14 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15  (1) , 290
Hyaluronic Acid-Modified Cisplatin-Encapsulated Poly(Lactic-co-Glycolic Acid) Magnetic Nanoparticles for Dual-Targeted NIR-Responsive Chemo-Photothermal Combination Cancer Therapy
Combination chemo-photothermal therapy with nanomaterials can reduce the dose of chemotherapeutic drugs required for effective cancer treatment by minimizing toxic side effects while improving survival times. Toward this end, we prepare hyaluronic acid (HA)-modified poly(lactic-co-glycolic acid) (PLGA) magnetic nanoparticles (MNP) for the CD44 receptor-mediated and magnetic field-guided dual-targeted delivery of cisplatin (CDDP). By co-encapsulating the CDDP and oleic acid-coated iron oxide MNP (IOMNP) in PLGA, the PMNPc was first prepared in a single emulsification/solvent evaporation step and successively surface modified with chitosan and HA to prepare the HA/PMNPc. Spherical HA/PMNPc nanoparticles of ~300 nm diameter can be prepared with 18 and 10% (w/w) loading content of CDDP and IOMNP and a pH-sensitive drug release to facilitate the endosomal release of the CDDP after intracellular uptake. This leads to the higher cytotoxicity of the HA/PMNPc toward the U87 glioblastoma cells than free CDDP with reduced IC50, a higher cell apoptosis rate, and the enhanced expression of cell apoptosis marker proteins. Furthermore, the nanoparticles show the hyperthermia effect toward U87 after short-term near-infrared (NIR) light exposure, which can further elevate the cell apoptosis/necrosis rate and upregulate the HSP70 protein expression due to the photothermal effects. The combined cancer therapeutic efficacy was studied in vivo using subcutaneously implanted U87 cells in nude mice. By using dual-targeted chemo-photothermal combination cancer therapy, the intravenously injected HA/PMNPc under magnetic field guidance and followed by NIR laser irradiation was demonstrated to be the most effective treatment modality by inhibiting the tumor growth and prolonging the survival time of the tumor-bearing nude mice.
- 14 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15  (1) , 290
Open AccessHyaluronic Acid-Modified Cisplatin-Encapsulated Poly(Lactic-co-Glycolic Acid) Magnetic Nanoparticles for Dual-Targeted NIR-Responsive Chemo-Photothermal Combination Cancer Therapy
Combination chemo-photothermal therapy with nanomaterials can reduce the dose of chemotherapeutic drugs required for effective cancer treatment by minimizing toxic side effects while improving survival times. Toward this end, we prepare hyaluronic acid (HA)-modified poly(lactic-co-glycolic acid) (PLGA) magnetic nanoparticles (MNP) for the CD44 receptor-mediated and magnetic field-guided dual-targeted delivery of cisplatin (CDDP). By co-encapsulating the CDDP and oleic acid-coated iron oxide MNP (IOMNP) in PLGA, the PMNPc was first prepared in a single emulsification/solvent evaporation step and successively surface modified with chitosan and HA to prepare the HA/PMNPc. Spherical HA/PMNPc nanoparticles of ~300 nm diameter can be prepared with 18 and 10% (w/w) loading content of CDDP and IOMNP and a pH-sensitive drug release to facilitate the endosomal release of the CDDP after intracellular uptake. This leads to the higher cytotoxicity of the HA/PMNPc toward the U87 glioblastoma cells than free CDDP with reduced IC50, a higher cell apoptosis rate, and the enhanced expression of cell apoptosis marker proteins. Furthermore, the nanoparticles show the hyperthermia effect toward U87 after short-term near-infrared (NIR) light exposure, which can further elevate the cell apoptosis/necrosis rate and upregulate the HSP70 protein expression due to the photothermal effects. The combined cancer therapeutic efficacy was studied in vivo using subcutaneously implanted U87 cells in nude mice. By using dual-targeted chemo-photothermal combination cancer therapy, the intravenously injected HA/PMNPc under magnetic field guidance and followed by NIR laser irradiation was demonstrated to be the most effective treatment modality by inhibiting the tumor growth and prolonging the survival time of the tumor-bearing nude mice.
- Open Access
- 3 January 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12  (1) , 163
Liposomal PHD2 Inhibitors and the Enhanced Efficacy in Stabilizing HIF-1Îą
Prolyl hydroxylase domain-containing protein 2 (PHD2) inhibition, which stabilizes hypoxia-inducible factor (HIF)-1Îą and thus triggers adaptation responses to hypoxia in cells, has become an important therapeutic target. Despite the proven high potency, small-molecule PHD2 inhibitors such as IOX2 may require a nanoformulation for favorable biodistribution to reduce off-target toxicity. A liposome formulation for improving the pharmacokinetics of an encapsulated drug while allowing a targeted delivery is a viable option. This study aimed to develop an efficient loading method that can encapsulate IOX2 and other PHD2 inhibitors with similar pharmacophore features in nanosized liposomes. Driven by a transmembrane calcium acetate gradient, a nearly 100% remote loading efficiency of IOX2 into liposomes was achieved with an optimized extraliposomal solution. The electron microscopy imaging revealed that IOX2 formed nanoprecipitates inside the liposomeâs interior compartments after loading. For drug efficacy, liposomal IOX2 outperformed the free drug in inducing the HIF-1Îą levels in cell experiments, especially when using a targeting ligand. This method also enabled two clinically used inhibitorsâvadadustat and roxadustatâto be loaded into liposomes with a high encapsulation efficiency, indicating its generality to load other heterocyclic glycinamide PHD2 inhibitors. We believe that the liposome formulation of PHD2 inhibitors, particularly in conjunction with active targeting, would have therapeutic potential for treating more specifically localized disease lesions.
- 3 January 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12  (1) , 163
Open AccessLiposomal PHD2 Inhibitors and the Enhanced Efficacy in Stabilizing HIF-1Îą
Prolyl hydroxylase domain-containing protein 2 (PHD2) inhibition, which stabilizes hypoxia-inducible factor (HIF)-1Îą and thus triggers adaptation responses to hypoxia in cells, has become an important therapeutic target. Despite the proven high potency, small-molecule PHD2 inhibitors such as IOX2 may require a nanoformulation for favorable biodistribution to reduce off-target toxicity. A liposome formulation for improving the pharmacokinetics of an encapsulated drug while allowing a targeted delivery is a viable option. This study aimed to develop an efficient loading method that can encapsulate IOX2 and other PHD2 inhibitors with similar pharmacophore features in nanosized liposomes. Driven by a transmembrane calcium acetate gradient, a nearly 100% remote loading efficiency of IOX2 into liposomes was achieved with an optimized extraliposomal solution. The electron microscopy imaging revealed that IOX2 formed nanoprecipitates inside the liposomeâs interior compartments after loading. For drug efficacy, liposomal IOX2 outperformed the free drug in inducing the HIF-1Îą levels in cell experiments, especially when using a targeting ligand. This method also enabled two clinically used inhibitorsâvadadustat and roxadustatâto be loaded into liposomes with a high encapsulation efficiency, indicating its generality to load other heterocyclic glycinamide PHD2 inhibitors. We believe that the liposome formulation of PHD2 inhibitors, particularly in conjunction with active targeting, would have therapeutic potential for treating more specifically localized disease lesions.
- 1 September 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 128, 112311
Magnetic and GRPR-targeted reduced graphene oxide/doxorubicin nanocomposite for dual-targeted chemo-photothermal cancer therapy
- 1 September 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 128, 112311
Magnetic and GRPR-targeted reduced graphene oxide/doxorubicin nanocomposite for dual-targeted chemo-photothermal cancer therapy
- Open Access
- 13 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21  (8) , 2690
Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy
Recombinant tissue plasminogen activator (rtPA) is the only thrombolytic agent that has been approved by the FDA for treatment of ischemic stroke. However, a high dose intravenous infusion is required to maintain effective drug concentration, owing to the short half-life of the thrombolytic drug, whereas a momentous limitation is the risk of bleeding. We envision a dual targeted strategy for rtPA delivery will be feasible to minimize the required dose of rtPA for treatment. For this purpose, rtPA and fibrin-avid peptide were co-immobilized to poly(lactic-co-glycolic acid) (PLGA) magnetic nanoparticles (PMNP) to prepare peptide/rtPA conjugated PMNPs (pPMNP-rtPA). During preparation, PMNP was first surface modified with avidin, which could interact with biotin. This is followed by binding PMNP-avidin with biotin-PEG-rtPA (or biotin-PEG-peptide), which was prepared beforehand by binding rtPA (or peptide) to biotin-PEG-maleimide while using click chemistry between maleimide and the single âSH group in rtPA (or peptide). The physicochemical property characterization indicated the successful preparation of the magnetic nanoparticles with full retention of rtPA fibrinolysis activity, while biological response studies underlined the high biocompatibility of all magnetic nanoparticles from cytotoxicity and hemolysis assays in vitro. The magnetic guidance and fibrin binding effects were also confirmed, which led to a higher thrombolysis rate in vitro using PMNP-rtPA or pPMNP-rtPA when compared to free rtPA after static or dynamic incubation with blood clots. Using pressure-dependent clot lysis model in a flow system, dual targeted pPMNP-rtPA could reduce the clot lysis time for reperfusion by 40% when compared to free rtPA at the same drug dosage. From in vivo targeted thrombolysis in a rat embolic model, pPMNP-rtPA was used at 20% of free rtPA dosage to restore the iliac blood flow in vascular thrombus that was created by injecting a blood clot to the hind limb area.
- 13 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21  (8) , 2690
Open AccessPreparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy
Recombinant tissue plasminogen activator (rtPA) is the only thrombolytic agent that has been approved by the FDA for treatment of ischemic stroke. However, a high dose intravenous infusion is required to maintain effective drug concentration, owing to the short half-life of the thrombolytic drug, whereas a momentous limitation is the risk of bleeding. We envision a dual targeted strategy for rtPA delivery will be feasible to minimize the required dose of rtPA for treatment. For this purpose, rtPA and fibrin-avid peptide were co-immobilized to poly(lactic-co-glycolic acid) (PLGA) magnetic nanoparticles (PMNP) to prepare peptide/rtPA conjugated PMNPs (pPMNP-rtPA). During preparation, PMNP was first surface modified with avidin, which could interact with biotin. This is followed by binding PMNP-avidin with biotin-PEG-rtPA (or biotin-PEG-peptide), which was prepared beforehand by binding rtPA (or peptide) to biotin-PEG-maleimide while using click chemistry between maleimide and the single âSH group in rtPA (or peptide). The physicochemical property characterization indicated the successful preparation of the magnetic nanoparticles with full retention of rtPA fibrinolysis activity, while biological response studies underlined the high biocompatibility of all magnetic nanoparticles from cytotoxicity and hemolysis assays in vitro. The magnetic guidance and fibrin binding effects were also confirmed, which led to a higher thrombolysis rate in vitro using PMNP-rtPA or pPMNP-rtPA when compared to free rtPA after static or dynamic incubation with blood clots. Using pressure-dependent clot lysis model in a flow system, dual targeted pPMNP-rtPA could reduce the clot lysis time for reperfusion by 40% when compared to free rtPA at the same drug dosage. From in vivo targeted thrombolysis in a rat embolic model, pPMNP-rtPA was used at 20% of free rtPA dosage to restore the iliac blood flow in vascular thrombus that was created by injecting a blood clot to the hind limb area.
- 1 October 2019
- Published by Elsevier in Chemical Engineering Journal
- Vol. 373, 720-733
Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy
- 1 October 2019
- Published by Elsevier in Chemical Engineering Journal
- Vol. 373, 720-733
Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy
- 1 March 2019
- Published by Elsevier in Journal of Magnetism and Magnetic Materials
- Vol. 474, 355-364
Hyaluronic acid modified bubble-generating magnetic liposomes for targeted delivery of doxorubicin
- 1 March 2019
- Published by Elsevier in Journal of Magnetism and Magnetic Materials
- Vol. 474, 355-364
Hyaluronic acid modified bubble-generating magnetic liposomes for targeted delivery of doxorubicin
- 1 March 2019
- Published by Elsevier in Journal of Magnetism and Magnetic Materials
- Vol. 473, 241-252
Dual targeted magnetic photosensitive liposomes for photothermal/photodynamic tumor therapy
- 1 March 2019
- Published by Elsevier in Journal of Magnetism and Magnetic Materials
- Vol. 473, 241-252
Dual targeted magnetic photosensitive liposomes for photothermal/photodynamic tumor therapy
- Open Access
Gelatin/Nanohyroxyapatite Cryogel Embedded Poly(lactic-co-glycolic Acid)/Nanohydroxyapatite Microsphere Hybrid Scaffolds for Simultaneous Bone Regeneration and Load-Bearing
It is desirable to combine load-bearing and bone regeneration capabilities in a single bone tissue engineering scaffold. For this purpose, we developed a high strength hybrid scaffold using a sintered poly(lactic-co-glycolic acid) (PLGA)/nanohydroxyapatite (nHAP) microsphere cavity fitted with gelatin/nHAP cryogel disks in the center. Osteo-conductive/osteo-inductive nHAP was incorporated in 250â500 Îźm PLGA microspheres at 40% (w/w) as the base matrix for the high strength cavity-shaped microsphere scaffold, while 20% (w/w) nHAP was incorporated into gelatin cryogels as an embedded core for bone regeneration purposes. The physico-chemical properties of the microsphere, cryogel, and hybrid scaffolds were characterized in detail. The ultimate stress and Youngâs modulus of the hybrid scaffold showed 25- and 21-fold increases from the cryogel scaffold. In vitro studies using rabbit bone marrow-derived stem cells (rBMSCs) in cryogel and hybrid scaffolds through DNA content, alkaline phosphatase activity, and mineral deposition by SEM/EDS, showed the prominence of both scaffolds in cell proliferation and osteogenic differentiation of rBMSCs in a normal medium. Calcium contents analysis, immunofluorescent staining of collagen I (COL I), and osteocalcin (OCN) and relative mRNA expression of COL I, OCN and osteopontin (OPN) confirmed in vitro differentiation of rBMSCs in the hybrid scaffold toward the bone lineage. From compression testing, the cell/hybrid scaffold construct showed a 1.93 times increase of Youngâs modulus from day 14 to day 28, due to mineral deposition. The relative mRNA expression of osteogenic marker genes COL I, OCN, and OPN showed 5.5, 18.7, and 7.2 folds increase from day 14 to day 28, respectively, confirming bone regeneration. From animal studies, the rBMSCs-seeded hybrid constructs could repair mid-diaphyseal tibia defects in rabbits, as evaluated by micro-computed tomography (Îź-CT) and histological analyses. The hybrid scaffold will be useful for bone regeneration in load-bearing areas.
Open AccessGelatin/Nanohyroxyapatite Cryogel Embedded Poly(lactic-co-glycolic Acid)/Nanohydroxyapatite Microsphere Hybrid Scaffolds for Simultaneous Bone Regeneration and Load-Bearing
It is desirable to combine load-bearing and bone regeneration capabilities in a single bone tissue engineering scaffold. For this purpose, we developed a high strength hybrid scaffold using a sintered poly(lactic-co-glycolic acid) (PLGA)/nanohydroxyapatite (nHAP) microsphere cavity fitted with gelatin/nHAP cryogel disks in the center. Osteo-conductive/osteo-inductive nHAP was incorporated in 250â500 Îźm PLGA microspheres at 40% (w/w) as the base matrix for the high strength cavity-shaped microsphere scaffold, while 20% (w/w) nHAP was incorporated into gelatin cryogels as an embedded core for bone regeneration purposes. The physico-chemical properties of the microsphere, cryogel, and hybrid scaffolds were characterized in detail. The ultimate stress and Youngâs modulus of the hybrid scaffold showed 25- and 21-fold increases from the cryogel scaffold. In vitro studies using rabbit bone marrow-derived stem cells (rBMSCs) in cryogel and hybrid scaffolds through DNA content, alkaline phosphatase activity, and mineral deposition by SEM/EDS, showed the prominence of both scaffolds in cell proliferation and osteogenic differentiation of rBMSCs in a normal medium. Calcium contents analysis, immunofluorescent staining of collagen I (COL I), and osteocalcin (OCN) and relative mRNA expression of COL I, OCN and osteopontin (OPN) confirmed in vitro differentiation of rBMSCs in the hybrid scaffold toward the bone lineage. From compression testing, the cell/hybrid scaffold construct showed a 1.93 times increase of Youngâs modulus from day 14 to day 28, due to mineral deposition. The relative mRNA expression of osteogenic marker genes COL I, OCN, and OPN showed 5.5, 18.7, and 7.2 folds increase from day 14 to day 28, respectively, confirming bone regeneration. From animal studies, the rBMSCs-seeded hybrid constructs could repair mid-diaphyseal tibia defects in rabbits, as evaluated by micro-computed tomography (Îź-CT) and histological analyses. The hybrid scaffold will be useful for bone regeneration in load-bearing areas.